Paying for Cancer Cures: Why Should It Be the Victims?

In her Washington Post column Megan McArdle tells readers that we are making great progress in developing cures for cancer, but then she warns these cures can be very expensive:

"But immune-based therapies are unlikely to ever be available for a few cents a dose, especially not the personalized ones. Of the immunotherapies we already have, Opdivo and Yervoy combination drug therapy can cost a quarter of a million dollars; CAR T-cell almost double that."

The part missing from this story is t...